PCSK9抑制性单克隆抗体妊娠期安全性:VigiBase®不平衡性分析
研究检索WHO全球药物警戒数据库VigiBase®,评估阿利西尤单抗与依洛尤单抗妊娠期暴露的不良事件报告信号。与全数据库及他汀类相比,自发性流产未显示报告不成比例信号。
要点
- VigiBase®中阿利西尤单抗和依洛尤单抗妊娠期暴露报告共45份,多数来自欧洲医疗专业人员。
- 自发性流产报告8份,与全数据库比较ROR 0.06(95%CI 0.03-0.12),与他汀类比较ROR 0.16(95%CI 0.08-0.32),均未构成信号。
- 无不成比例信号不等于安全,需定期重复分析以确认结果。
核心结论
- 当前VigiBase®数据未显示阿利西尤单抗和依洛尤单抗妊娠期自发性流产报告不成比例增加。
主要发现
- 共45份妊娠期暴露报告,依洛尤单抗31份、阿利西尤单抗14份;25份(55.6%)来自欧洲,35份(77.8%)由医疗专业人员报告。
- 患者中位年龄37岁(25-75百分位32-41岁);36份(80.0%)为妊娠期药物暴露,4份(8.9%)为妊娠期父方暴露,3份(6.7%)为哺乳期暴露,2份暴露时间未知。
- 20份(57.8%)仅报告药物暴露,19份(42.2%)报告妊娠结局但无特定母体毒性或出生缺陷模式。
- 自发性流产报告8份,与全数据库比较ROR 0.06(95%CI 0.03-0.12),与他汀类比较ROR 0.16(95%CI 0.08-0.32),均未构成不成比例报告信号。
临床怎么用
- 临床药师可参考本分析结果,但不应将缺乏不成比例信号视为妊娠期安全性的确证证据。
- 对妊娠期暴露于阿利西尤单抗或依洛尤单抗的患者,仍需个体化评估并持续监测妊娠结局。
局限性
- 不成比例分析依赖于VigiBase®中逐步累积的报告数量,结果需定期重复验证。
- 报告数据可能存在漏报、报告质量不一及混杂因素,且缺乏特定母体毒性或出生缺陷模式的详细信息。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Safety data on the use of monoclonal antibodies inhibiting proprotein convertase subtilisin/kexin type 9 in pregnancy are scarce. This study queried VigiBase®, the World Health Organization global pharmacovigilance database, to search for signals of disproportionate reporting for pregnancy outcomes with alirocumab and evolocumab. As of November 22, 2023, there were 45 safety reports of exposure to evolocumab (N = 31) and alirocumab (N = 14) in pregnancy. Most of them originated from Europe (N = 25, 55.6%) and were more frequently reported by healthcare professionals (N = 35, 77.8%). Median patient age was 37 years (25th-75th percentiles; 32-41 years). Drug exposure occurred during pregnancy in 36 (80.0%) safety reports, via paternal exposure during pregnancy in four (8.9%), during lactation in three (6.7%), and in two safety reports the time of drug exposure remained unknown. Twenty safety reports (57.8%) merely reported drug exposure, while 19 (42.2%) also reported pregnancy outcomes, however, without specific maternal toxicities or patterns of birth defects. Spontaneous abortion was reported in eight safety reports without representing a signal of disproportionate reporting compared with either the full database (reporting odds ratio, ROR, 0.06 95% confidence interval, CI 0.03-0.12) or statins (ROR 0.16, 95% CI 0.08-0.32). In conclusion, this study showed that, currently, there are no signals of increased reporting of spontaneous abortion with alirocumab and evolocumab compared with the full database and statins in VigiBase®. Notwithstanding, lack of disproportionality is not synonymous with safety and, as disproportionality analyses depend on the number of safety reports that progressively accumulate in VigiBase®, they should be repeated at regular intervals to confirm the results of the present study.
引用
- Noseda R, Bedussi F, Panchaud A, et al. Safety of Monoclonal Antibodies Inhibiting PCSK9 in Pregnancy: Disproportionality Analysis in VigiBase®. Clin Pharmacol Ther. 2024. PMID: 38637956. doi:10.1002/cpt.3269
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。